CClinicalTrials.gg
Not yet recruitingNCT07843433IN-TIMEUpdated Sep 28, 2026

ImprovINg the TIMEly Diagnosis and Treatment of Cancer and Cardio-metabolic Diseases in People With Mental Disorders: Reducing Health Disparities Through Integrated Care

An observational study in Mental Health, Cancer and Cardiometabolic Diseases, sponsored by IRCCS San Raffaele. Not yet recruiting. Open to participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by IRCCS San Raffaele · Observational

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
120
Ages
40 Years to 70 Years
Sex
All
01

Study summary

One in five people in Italy has a mental disorder, with depression being the most common and schizophrenia the most severe. People with mental illness have a higher risk of cardio-metabolic and oncologic comorbidities. They also face disparities in accessing appropriate care, with a 20-year life expectancy reduction. IN-TIME will employ an innovative and highly interdisciplinary approach to characterize barriers to healthcare in people with mental illness for informing interventions and enhancing screening, diagnostic pathways and health outcomes. The project will provide: 1) population-based evidence and characterization of disparities in diagnosis and care for cancer and cardio-metabolic disorders; 2) a fine-grained identification of modifiable barriers, such as those relating to stigma and communication; 3) change promoting interventions, including a policy brief to orient clinical guidelines and best practice to reduce stigma, improve doctor-patient communication and optimize care.

02

Conditions studied

  • Mental Health
  • Cancer
  • Cardiometabolic Diseases
03

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Potential participants will be identified through outpatient clinics at IRCCS Ospedale San Raffaele and ASST Santi Paolo e Carlo. Eligible participants will be approached and invited to participate in the study and will undergo screening based on predefined eligibility criteria. The target population includes adults aged 40-70 years with schizophrenia spectrum disorder, depressive disorder, or bipolar disorder. A total of 120 participants will be recruited, 60 at each study site, with both sexes included.

Inclusion criteria

  • Age 40-70 years;
  • ICD-10 diagnosis of schizophrenia spectrum disorder (F20-F29), depressive disorder (F32-F33), or bipolar disorder (F31);
  • Ability to provide written informed consent.
  • Both sexes are eligible.
  • Participants recruited at IRCCS Ospedale San Raffaele or ASST Santi Paolo e Carlo.

Exclusion criteria

Exclusion Criteria:

  • Age \<40 years or >70 years.
  • Inability to provide informed consent.
  • Absence of an ICD-10 diagnosis of schizophrenia spectrum disorder (F20-F29), depressive disorder (F32-F33), or bipolar disorder (F31).
04

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
120 participants (estimated)
Patient registry
No

Groups and cohorts

  • People with severe mental disorders

    Other: Not applicable - observational study

Interventions

  • OtherNot applicable - observational study

    Not applicable - observational study

05

What researchers measure

Primary outcomes

  1. Timely access to cancer and cardiometabolic screening and early diagnosis and related healthcare barriers

    For the observational cross-sectional part of the study, the investigators will assess barriers to timely access to cancer and cardiometabolic screening, diagnosis and care in adult patients with schizophrenia spectrum disorder, depressive disorder or bipolar disorder. Participants will undergo standardized assessments and an ad-hoc semi-structured interview exploring personal experiences of healthcare access, screening, diagnostic pathways, communication with healthcare professionals, and perceived barriers and facilitators to care. Interviews will be audio-recorded and analysed using qualitative methods and Natural Language Processing (NLP). A total of 120 participants will be enrolled at two sites: IRCCS Ospedale San Raffaele (n=60) and ASST Santi Paolo e Carlo (n=60).

    Time frame: Baseline

06

Study locations

No study locations are listed for this record.

07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07843433
Lead sponsor
IRCCS San Raffaele
Collaborators
ASST Santi Paolo e Carlo, Istituto Universitario di Studi Superiori - IUSS, HPA (Health Protection Agency) of the Metropolitan City of Milan, DG Welfare Regione Lombardia, University College, London, Accademia Lombarda di Sanità Pubblica
Responsible party
Cristina Renzi (Associate Professor and Medical Doctor, IRCCS San Raffaele) — Principal investigator
First posted
Sep 28, 2026
Start date
Nov 2026 (estimated)
Primary completion
Jun 2029 (estimated)
Completion
Nov 2029 (estimated)
Last update
Sep 28, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion